306 related articles for article (PubMed ID: 22182579)
1. Synthesis and biochemical analysis of 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-N-hydroxy-octanediamides as inhibitors of human histone deacetylases.
Henkes LM; Haus P; Jäger F; Ludwig J; Meyer-Almes FJ
Bioorg Med Chem; 2012 Jan; 20(2):985-95. PubMed ID: 22182579
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase.
Huang WJ; Chen CC; Chao SW; Lee SS; Hsu FL; Lu YL; Hung MF; Chang CI
ChemMedChem; 2010 Apr; 5(4):598-607. PubMed ID: 20209563
[TBL] [Abstract][Full Text] [Related]
3. Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
Oanh DT; Hai HV; Park SH; Kim HJ; Han BW; Kim HS; Hong JT; Han SB; Hue VT; Nam NH
Bioorg Med Chem Lett; 2011 Dec; 21(24):7509-12. PubMed ID: 22036991
[TBL] [Abstract][Full Text] [Related]
4. Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.
Thaler F; Mercurio C
ChemMedChem; 2014 Mar; 9(3):523-6. PubMed ID: 24730063
[TBL] [Abstract][Full Text] [Related]
5. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.
Codd R; Braich N; Liu J; Soe CZ; Pakchung AA
Int J Biochem Cell Biol; 2009 Apr; 41(4):736-9. PubMed ID: 18725319
[TBL] [Abstract][Full Text] [Related]
6. Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.
Botta CB; Cabri W; Cini E; De Cesare L; Fattorusso C; Giannini G; Persico M; Petrella A; Rondinelli F; Rodriquez M; Russo A; Taddei M
J Med Chem; 2011 Apr; 54(7):2165-82. PubMed ID: 21417297
[TBL] [Abstract][Full Text] [Related]
7. A structure-based virtual screening approach toward the discovery of histone deacetylase inhibitors: identification of promising zinc-chelating groups.
Park H; Kim S; Kim YE; Lim SJ
ChemMedChem; 2010 Apr; 5(4):591-7. PubMed ID: 20157916
[TBL] [Abstract][Full Text] [Related]
8. Identification of selective class II histone deacetylase inhibitors using a novel dual-parameter binding assay based on fluorescence anisotropy and lifetime.
Haus P; Korbus M; Schröder M; Meyer-Almes FJ
J Biomol Screen; 2011 Dec; 16(10):1206-16. PubMed ID: 22027638
[TBL] [Abstract][Full Text] [Related]
9. Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors.
Rossi C; Porcelloni M; D'Andrea P; Fincham CI; Ettorre A; Mauro S; Squarcia A; Bigioni M; Parlani M; Nardelli F; Binaschi M; Maggi CA; Fattori D
Bioorg Med Chem Lett; 2011 Apr; 21(8):2305-8. PubMed ID: 21420859
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors.
Huang WJ; Chen CC; Chao SW; Yu CC; Yang CY; Guh JH; Lin YC; Kuo CI; Yang P; Chang CI
Eur J Med Chem; 2011 Sep; 46(9):4042-9. PubMed ID: 21712146
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
Pabba C; Gregg BT; Kitchen DB; Chen ZJ; Judkins A
Bioorg Med Chem Lett; 2011 Jan; 21(1):324-8. PubMed ID: 21109435
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, evaluation and molecular modeling of cyclic tetrapeptide histone deacetylase inhibitors as anticancer agents.
Huang D; Li X; Sun L; Xiu Z; Nishino N
J Pept Sci; 2012 Apr; 18(4):242-51. PubMed ID: 22253009
[TBL] [Abstract][Full Text] [Related]
13. Carbamate prodrug concept for hydroxamate HDAC inhibitors.
Schlimme S; Hauser AT; Carafa V; Heinke R; Kannan S; Stolfa DA; Cellamare S; Carotti A; Altucci L; Jung M; Sippl W
ChemMedChem; 2011 Jul; 6(7):1193-8. PubMed ID: 21416613
[No Abstract] [Full Text] [Related]
14. Thiol versus hydroxamate as zinc binding group in HDAC inhibition: An ab initio QM/MM molecular dynamics study.
Gong W; Wu R; Zhang Y
J Comput Chem; 2015 Nov; 36(30):2228-35. PubMed ID: 26452222
[TBL] [Abstract][Full Text] [Related]
15. New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations.
Mai A; Valente S; Nebbioso A; Simeoni S; Ragno R; Massa S; Brosch G; De Bellis F; Manzo F; Altucci L
Int J Biochem Cell Biol; 2009 Jan; 41(1):235-47. PubMed ID: 18834955
[TBL] [Abstract][Full Text] [Related]
16. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.
Zhang Y; Feng J; Liu C; Zhang L; Jiao J; Fang H; Su L; Zhang X; Zhang J; Li M; Wang B; Xu W
Bioorg Med Chem; 2010 Mar; 18(5):1761-72. PubMed ID: 20171895
[TBL] [Abstract][Full Text] [Related]
18. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.
Finnin MS; Donigian JR; Cohen A; Richon VM; Rifkind RA; Marks PA; Breslow R; Pavletich NP
Nature; 1999 Sep; 401(6749):188-93. PubMed ID: 10490031
[TBL] [Abstract][Full Text] [Related]
19. SAHA Capture Compound--a novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders.
Fischer JJ; Michaelis S; Schrey AK; Diehl A; Graebner OY; Ungewiss J; Horzowski S; Glinski M; Kroll F; Dreger M; Koester H
Proteomics; 2011 Oct; 11(20):4096-104. PubMed ID: 21898820
[TBL] [Abstract][Full Text] [Related]
20. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
